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In the face of the worldwide threat of severe acute respiratory syndrome (SARS)
to human life, some of the most urgent challenges are to develop fast and accurate
analytical methods for early diagnosis of this disease as well as to create a safe
anti-viral vaccine for prevention. To these ends, we investigated the antigenicity of
the spike protein (S protein), a major structural protein in the SARS-coronavirus
(SARS-CoV). Based upon the theoretical analysis for hydrophobicity of the S pro-
tein, 18 peptides were synthesized. Using Enzyme-Linked Immunosorbent Assay
(ELISA), these peptides were screened in the sera from SARS patients. According
to these results, two fragments of the S gene were amplified by PCR and cloned
into pET-32a. Both S fragments were expressed in the BL-21 strain and further
purified with an affinity chromatography. These recombinant S fragments were
confirmed to have positive cross-reactions with SARS sera, either by Western blot
or by ELISA. Our results demonstrated that the potential epitope regions were
located at Codons 469-882 in the S protein, and one epitope site was located at
Codons 599-620. Identification of antigenic regions in the SARS-CoV S protein
may be important for the functional studies of this virus or the development of
clinical diagnosis.
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Introduction
Severe acute respiratory syndrome (SARS) has been
considered a worldwide threat to health since it was
initially reported in Guangdong province at the end
of 2002 (1 ). To control the spread of SARS, the
World Health Organization (WHO) coordinated ex-
traordinary collaborations among laboratories around
the world to identify the causative agent of SARS. In
April 2003, WHO announced that a new pathogen,
the SARS-coronavirus (SARS-CoV), a member of the
coronavirus family never seen before in humans, was
the cause of SARS (2 , 3 ). Subsequently, a number of
laboratories unraveled the genetic information of the
SARS-CoV (4 − 6 ). The immense challenge remains
to elucidate the mechanisms by which the virus func-
tions and causes illness based on the viral genomic
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information. Fortunately, outbreaks of SARS around
the world have begun to dwindle. However, we must
realize that our knowledge of this disease is still very
limited (7 ). It is still unknown how such a new deadly
coronavirus emerged in humans. There is no expla-
nation for what viral or host factors make the disease
so infectious, and no approved anti-SARS-CoV drugs
have been developed. In short, SARS research is still
in its early phase, but is facing urgent clinical de-
mands.
The SARS-CoV has four structural proteins, spike
(S), envelope (E), membrane (M) and nucleocapsid
(N), which function during host cell entry, virion mor-
phogenesis and release (8 ). The S protein, with its
size of 1,255 amino acids and 24 glycosylation sites, is
the largest structural protein in the SARS-CoV (5 ).
Since the S protein is a major viral component of
the SARS-CoV to directly attach to host cells, details
about its antigenicity can enhance our understanding
of pathogenesis as well as the development of diagnos-
tic approaches (9 ).
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The amino acid sequence of the S protein is signif-
icantly different from other coronaviruses, with only
24% pairwise amino acid identity (4 ). The topology
of the S protein in SARS-CoV is similar to that of
other coronavirus, which usually have a huge amount
of ectodomains and short transmembrane spans (10 ).
The majority of amino acids of the SARS-CoV S pro-
tein at the N-terminus (residues 14 to 1,195) were
found on the outside of the viral particle, while only 13
amino acids at the C-terminus were embedded in the
viral membrane (5 ). The configuration of the SARS-
CoV S protein exposed on the viral surface may be
different from those of other coronaviruses. In nu-
merous coronaviruses, a furin-like protease cleaves the
full-length S protein into two similar-sized fragments,
a peripheral S1 and a membrane anchored S2, dur-
ing viral maturation at the trans-Golgi network. The
two S fragments play different roles during viral in-
fection. The peripheral S1 portion can independently
bind cellular receptors while the integral membrane
S2 portion is required to mediate fusion of vial and
cellular membranes (11 ). Noncovalent interactions
coordinate S1 and S2 to attack a target cell. It has
been widely accepted that the formation of the S1-
S2 complex is a key event where coronavirial virion
is recognized by the membrane of the host cell (12 ).
For instance, the S protein of murine hepatitis virus
(MHV) was not captured by its receptors until the S1-
S2 oligomers were formed (13 ). Interestingly, there is
no protease cleavage site in the SARS-CoV S protein;
thus, this protein is probably not cleaved into S1 and
S2 subunits (4 ). Does this mean that the SARS-CoV
may conduct different infection mechanisms to host
cells without intermolecular cleavage? Is it possible
to form an uncleaved S oligomer in the SARS-CoV S
protein during infection? To address these questions,
immunoassay is a powerful tool that uses specific an-
tibodies to define different regions in the S protein.
Thus, we embarked on the studies to assess the S anti-
genic regions.
A study was done to investigate the S antigenic re-
gions with a strategy developed in our lab. According
to theoretical estimation, we first synthesized 18 pep-
tides derived from the S protein. These peptides were
screened in the sera from SARS patients using ELISA
measurement. Based on the ELISA data, two trun-
cated S recombinants were designed and expressed in
the BL-21 strain. With confirmation of immunoac-
tivities for the two recombinant S proteins, we have
demonstrated that an epitope site is located around
Codons 599-620 in the S protein.
Results and Discussion
The S protein is one of the major anti-
genic proteins in SARS structural pro-
teins
The extracted proteins from Vero-E6 cells infected
by the SARS-CoV were separated by SDS-PAGE
(12% polyacrylamide), transblotted onto a PVDF
(Polyvinylidene Fluoride) membrane and immuno-
recognized by antibodies in the sera from SARS pa-
tients. As shown in Figure 1, the cell extracts were
analyzed by Western blot using three SARS sera. Al-
though individual patient sera display different im-
munoreactivities against the same infected cell lysate,
the major immunostaining bands are located around
two regions (Figure 1), 50 kDa and 120-240 kDa. Be-
Fig. 1 The Western blot patterns of the immunoreac-
tive proteins in Vero-E6 cells infected by the SARS-CoV.
Each lane was loaded with 50 mg of the protein from the
lysate of Vero-E6 cells. Lane 1: control, the serum from a
healthy donor as the primary antibody; Lane 2-4: SARS-
CoV, the sera from SARS patients as primary antibodies;
Lane 5: standard protein markers.
cause the molecular weight (MW) of the N protein is
46 kDa, the protein band near to 50 kDa is reasoned
to be the N protein. The N protein bands examined
in this study have shown a constant expression; nev-
ertheless, the immunostained bands around 120-240
kDa do not display a constant pattern. These bands
are likely to be the S protein because the masses of
these protein bands are over 120 kDa. Spike pro-
teins have been reported to have multiple glycosyla-
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tion sites (14 ). Therefore, it is not surprising that the
SARS-CoV S proteins may show apparently different
molecular weights due to variable extents in glycosy-
lated modifications during infection. To confirm the
bands around 120-240 kDa, these bands were excised
and completely digested by trypsin. The tryptic frag-
ments were analyzed by mass spectrometry to identify
the composition of peptides (Figure 2). The results
from searching the peptide demonstrated that the S
proteins are the major components in these gel bands.
The sequence coverage based on the data of matched
peptides is 72.2% for the S protein.
A
B
Fig. 2 Analysis of mass spectrometry for the protein bands located between 124 to 209 kDa and recognized by SARS-
CoV sera in Western blot. A. Base peak ion chromatogram of trypsinized peptides from a piece of the excised gel after
in-gel digestion. B. The tandem mass spectra (MS/MS) for parent ion 1011.44 (sequence: QLSSNFGAISSVLNDILSR).
Serological studies on coronaviruses have shown
the existence of at least three antigenic groups within
the family. For instance, the human coronavirus
(HCV)-229E and the canine coronavirus (CCV) be-
long to Group I, MHV to Group II and infectious
bronchitis virus (IBV) to Group III (15 ). Viruses
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within each subgroup have partial antigenic cross-
reactivity based on the S proteins (16 ). Koch et
al. analyzed the antigenic structure of the S protein
from IBV, in which six antigenic sites were located
at S1 and two were at S2 (17 ). Since the S1 pro-
tein is responsible for the attachment to cellular host
membranes, it is not surprising that this protein is
stronger in antigenicity than the S2 protein. There-
fore, in many coronaviruses, the S1 protein has been
confirmed to correlate with serotype (18 ). Identifi-
cation of antigenic sites on the S1 protein has shown
its significance for virus detection and classification
(18 ). In our Western blot experiment, the SARS-CoV
S protein was also found to be a major antigenic pro-
tein. Does the SARS-CoV S protein have any homol-
ogy to other coronavirus S proteins in the antigenic
structure? Does the antigenic site on the SARS-CoV
S protein appear biological significance during SARS
infection? To address these questions, we extended
our studies to search for the antigenic site(s) of this
protein.
Screening the S antigenic sites with syn-
thesized peptides
Naturally, a key question for searching for antigenic
sites is how to select potential fragments among over
1,000 amino acids in the S protein. To select the
candidates for the antigenic peptide, we used sev-
eral theoretical calculations to estimate the biophys-
ical parameters of the peptides along the S protein
sequences. Specifically, we looked for high local hy-
drophilicity, the charged residues on the exposed pro-
tein surface, and accessible surface area. From Figure
3 (upper panel), the hydropathy plot indicates that
most regions of the S protein are very hydrophobic.
Hence, we only selected 18 peptides derived from the S
protein. These peptides, sized from 16-25 amino acid
residues, possess relatively low hydrophobicity scores
compared to the other regions of the S protein. The
synthesized peptides were coated on microtiter plates
as antigens and screened in the SARS sera (31 cases)
as antibodies in ELISA experiments.
Fig. 3 Evaluation of the detection rates of 18 synthesized peptides spanning the SARS-CoV S protein. The upper
graph shows hydropathy plots and the lower graph indicates the detection rates of synthesized peptides against 31 sera
from SARS patients by using ELISA.
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The correlations between hydrophobicity and im-
munoreactive detection rates are shown in Figure 3.
Although 18 peptides were tested, only the peptide
S599 located at Codons 599-620 (QDVNCTDVSTAI-
HADQLTPAWR) shows a significant immunoreactiv-
ity to SARS sera. This peptide reacted to over 80% of
patient sera and responded negative to all of the nor-
mal sera. The fact that the major synthesized pep-
tides had low immunoresponses against SARS sera
could be resulted from two possibilities, 1) the S pro-
tein may contain few epitope sites; 2) some epitope
sites may have been missed by our experimental de-
sign.
According to the cleavage model of S proteins, the
S2 protein is quite conserved, whereas the S1 pro-
tein contains an extensive heterogeneity in its amino
acid sequence (19 ). In some coronaviruses, the cel-
lular receptor binding regions with the hypervariable
sequences are located at the N-terminus of the S1 pro-
tein. The tropism determinant of the MHV S1 pro-
tein is located in the region of amino acid residues
from 456 to 592 nt (20 ). The neutralization site of
the feline infectious peritonitis virus (FIPV) is located
in the region of amino acid residues from 480 to 649
nt (21 ). Interestingly, these sites were also found to
act as antigenic sites in these viruses. MHV 4 is a
highly neurotropic virus that produces acute fatal en-
cephalitis in mice. Once amino acid residues in this
region are singly or multiply deleted, the neuroviru-
lence would be significantly reduced (20 ). Therefore,
developing a specific antibody (monoclonal antibod-
ies) against these regions could help to further under-
stand the pathogenesis of coronaviruses. Though the
SARS-CoV S protein could not be cleaved into two
subunits during infection, its antigenic region(s) may
be somehow similar to other coronavirus S proteins
depending on its folding state. More importantly, the
S peptide located at Codons 599-620 is in a region
that exists in both MHV and FIPV with antigenic
and neutralized functions. Whether this site could
bind to a host cell and cause the pathogenesis of the
SARS-CoV is a tempting topic for further studies.
To further confirm the immunoreactive function of
the peptide S599, we examined whether this peptide
could compete with the SARS-CoV to bind the anti-
bodies in SARS sera. If a peptide really mimics an
epitope site in this virus, it should elicit an immunore-
sponse and neutralize the immunoreaction in ELISA.
In previous ELISA tests, the peptide S599 with differ-
ent concentrations was mixed with the patient sera for
30 min. The extracted proteins from the SARS-CoV
were coated onto microtiter plates followed by incu-
bation of the mixed sera for ELISA measurement. As
shown in Figure 4, the ELISA reactivities were atten-
uated with the increase of the peptide concentrations
in the SARS sera. Thus, this competition experiment
has strengthened our argument that the peptide S599
represents one epitope site in the S protein.
Fig. 4 Peptide competition experiment in ELISA. Prior
to ELISA, the sera from SARS patients were incubated
with the peptide S599 in different concentrations. Then
the mixtures were incubated with the extraction of the
SARS-CoV coated on microtiter plates for further ELISA
measurement. The competition experiment at each con-
centration was tested in parallel for four times, and four
patient sera were used for the test.
Cloning and expression of the S frag-
ments around S599
As described above, the peptide S599 is 22 amino
acids long and reacts 80% of the SARS sera. Ob-
viously, it is not an ideal antigen because about 20%
positive cases were missed during ELISA detection.
How can more sensitive antigen(s) be developed with
the knowledge we have gained about S599? Coro-
navirus has a number of antigenic sites that often
form a cluster around certain regions. For instance,
two vicinal antigenic domains in bovine coronavirus
(BCV) span from amino acids 351 to 768 nt (22 )
and the FIPV antigenic regions cross from 480 to
649 nt (21 ). Therefore, we have designed to express
two large S fragments with MW around 30 kDa. In
these fragments, the peptide S599 is a core antigenic
element. Centered on this sequence, the recombi-
nant S469−749 extends 130 amino acids toward the N-
terminus of the S protein, and S602−882 expresses 262
amino acids to the C-terminus of the S protein.
To amplify the S gene fragments, the cDNA re-
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versely transcripted from the SARS-CoV RNA was
used as the template, and two pairs of primers,
S469−749 and S602−882, were synthesized (see Materials
and Methods). Figure 5 shows that the sizes of PCR
products coincide well with the theoretical estimation
based upon the genomic sequence, 844 and 846 bp, for
S469−749 and S602−882, respectively. Both PCR prod-
ucts were amplified with two restriction sites, BamH
I at 5′ and Xho I at 3′. These fragments were fur-
ther digested by enzymes and inserted into a bacte-
rial expression vector pET32a to generate the expres-
sion vectors pET32a-S469−749 and pET32a-S602−882.
The ligation products were examined by restriction
digestion (Figure 5) and further confirmed by DNA
sequencing.
Fig. 5 Construction of the S truncated recombinants
into an expression vector, pET30a. Lane 1: DNA
ladder; Lanes 2 and 7: the S fragments amplified by
PCR, S469−749 and S602−882, respectively; Lanes 3 and
8: pET30a vector only; Lanea 4 and 9: pET30a-S469−749
and pET30a-S602−882 vectors, respectively; Lanes 5 and
10: pET30a digested by Xho I and BamH I; Lanes 6
and 11: pET30a-S469−749 and pET30a-S602−882 vectors
digested by Xho I and BamH I, respectively.
The two expression vectors were transformed
into the BL-21 strain and the proteins were ex-
pressed by inducement of IPTG (isopropyl-β-D-
thiogalactopyranoside). Since the S protein is quite
hydrophobic, its recombinant may not be easily sol-
uble in bacterial cytosol. A tag of thioredoxin was
added at the N-terminus of S fragments to induce the
formation of soluble S recombinant proteins. Both
S recombinants were successfully expressed in BL-21
when induced by IPTG (Figure 6). However, the ex-
pression products were in inclusionbodies even with
the soluble tag of thioredoxin. Figure 7 displays that
the molecular weights of the expressed S proteins are
approximately 50 kDa, which are much higher than
the values of theoretical estimation, 30 kDa, for both
S469−749 and S602−882. Since there is no protease di-
gestion after expression and purification, the apparent
MW representing the fusion protein consisting of S
fragment and thioredoxin is not surprising. To obtain
a high protein yield, the bacterial pellets were treated
with 8 M urea followed by a strong probe sonication
to completely dissolve the inclusions. Since the dena-
tured proteins retained an affinity to Ni2+, a Ni-NTA
column was effectively applied to the purification of
these recombinants. As shown in Figure 7, the re-
combinant proteins purified by Ni-NTA were of high
purity (>95%).
Fig. 6 SDS-PAGE analysis of expression and purification
of the recombinant S proteins. Lane 1: protein ladder;
Lanes 2 and 4: the lysate of BL-21 containing pET30a-
S469−749 and pET30a-S602−882 vectors without IPTG in-
ducement, respectively; Lanes 3 and 5: the lysate of BL-21
containing pET30a-S469−749 and pET30a-S602−882 vectors
under IPTG inducement, respectively; Lanes 6 and 7: pu-
rified recombinant S proteins, S469−749 and S602−882, re-
spectively.
Fig. 7 Western blot analysis for the recombinant S pro-
teins using SARS sera as primary antibodies. Lane 1: Pro-
tein ladder. Lanes 2, 4 and 6 are loaded with the S469−749
protein. Lanes 3, 5 and 7 are loaded with S602−882 pro-
tein. Three patient sera were used for this experiment. Of
these lanes, 2 and 3, 4 and 5, and 6 and 7 share the same
patient serum, respectively.
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Immunoassay for the S recombinant
proteins by Western blot and ELISA
The S recombinants were further examined on their
immunoresponses against the antibodies raised from
SARS sera. In Western blot, both recombinant pro-
teins were recognized by all of the three patient sera.
Notably, the two S proteins showed slightly different
immunoresponses, in which the S602−882 protein had
significantly higher immunostaining intensity than
that of the S469−749 protein. Similar phenomenon was
observed in all the three tested patient sera, indicat-
ing that the S602−882 protein may contain a strong
epitope side to elicit the immunoresponse. The two S
recombinants share almost 50% amino acid sequence,
that is, 147 amino acids at the C-terminus of S469−749
are identical with the N-terminus of S602−882. The se-
quence of the peptide S599 is mainly located within
S602−882. Hence, this result provides more evidence
that the site around Codons 599-620 is an antigenic-
ity region. Furthermore, S469−749 does display pos-
itive immunoreaction to SARS sera even though it
only contains three amino acids from the peptide 599.
Normally, a short peptide with three amino acids is
impossible to form an antigenic site. A logical deduc-
tion is that the region neighboring the three amino
acids is antigenic or there is another epitope site(s) in
the S469−749 protein.
The two S recombinant proteins were screened by
SARS sera with ELISA. Six sera, four from SARS
patients and two from controls, were examined. The
ELISA data revealed that both S469−749 and S602−882
proteins had strong positive reactions to patient sera
but negative to normal sera.
Materials and Methods
The E. coli strains, DH5α and BL-21 (λCE6), were
purchased from Shanghai Dingguo Co. All primers
were synthesized by Shanghai Ding’an Co. The bac-
terial protein expression vector, pET-32a, was pur-
chased from Novagen (Darmstadt, Germany). Re-
striction enzymes and nitro-blue tetrazolium chloride
(NBT) and 5-bromo-4-chloro-3′-indolyphosphate p-
toluidine salt (BCIP) were obtained from Promega
(Madison, USA). Taq DNA polymerase and the re-
lated PCR reagents were from Invitrogen (Carls-
bad, USA). Ni-NTA resin was purchased from Qiagen
(Hilden, Germany). The antibody anti-human IgG
conjugated with alkaline phosphatase was purchased
from Beijing Zhongshan Company.
Sera of SARS patients were from hospitals in Bei-
jing and the control sera were obtained from healthy
volunteers. The clinical diagnostic criteria for SARS
followed the Clinical Description of SARS were re-
leased by WHO.
The SARS-CoV BJ01 strain cultured by the
Microbe Epidemic Institute in Chinese Academy
of Military Medical Sciences was used in this re-
search. Its genome was sequenced by Beijing Ge-
nomics Institute (BGI). All of the S protein fragments
were designed based upon this genomic sequence
(http://www.ncbi.nlm.nih.gov, GI: 30275666).
The SARS virus was propagated on Vero-E6 cells
as described before in the Microbe Epidemic Insti-
tute (23 ). After viral propagation, the cells were har-
vested and placed at 70˚C for 2 h to inactivate the
virus. The inactivated infected Vero-E6 cells in cul-
ture medium were concentrated by polyethylene gly-
col (PEG) 20,000 followed by cell lysis and protein
denatureation with 8 M urea. The cell lysate was fur-
ther sonicated with a probe sonicator and centrifuged
at 13,000 g to remove the insoluble debris. The su-
pernatant was used for Western blot and ELISA de-
terminations.
The amino acid sequence of the S protein was
downloaded into the ProtScale program at the Swiss
Institute of Bioinformatics (SIB) to analyze the
physical characteristics of the proteins, such as
hydrophilicity, hydrophobicity, accessible residues,
buried residues, MW, and pI values. Forty-one pep-
tides ranging in size from 16 to 25 amino acid residues
were selected for synthesis. All of the peptides were
synthesized commercially by Chinese Peptide Co.,
Hangzhou. The synthesized peptides were character-
ized by HPLC and mass spectrometry.
The viral genomic RNA was prepared using TRI-
zol reagent (Invitrogen). First-strand cDNA syn-
thesis was carried out as described in the com-
pany manual (SuperscriptTM kit). Two pairs of
primers were designed to amplify S469−749 and
S602−882 fragments based upon the open read-
ing frame (ORF) of the S gene from BJ01 SARS
genome. Specifically, the sequences of these primers
are, 5′CGGATCCCCACCTGCTCTTAATTGTTA
(S469−749 forward with a BamH I restriction site at
the 5′ end), 5′CCGCTCGAGGAGTGCACGATTTA-
GTTGTGT (S469−749 reverse with a Xho I restriction
site at the 3′ end), 5′CGGGATCCAACTGCACTGA-
TGTTTCTACA (S602−882 forward with a BamH I
restriction site at the 5′ end), and CCGCTCGAG-
GCATAGCAAAAGGTATTTGAAG (S602−882 re-
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verse with a Xho I restriction site at the 3′ end).
PCR products and pET-32a vector were excised
with BamH I and Xho I overnight at 37˚C, puri-
fied from agarose gel and ligated with each other at
room temperature for 3 h. The ligation products
were transformed into DH5α strains. The expression
vectors with S gene insertions were checked first by
restriction digestion and further confirmed by DNA
sequencing. The correct vectors were transformed
into BL-21 (λCE6) for protein expression (24 ).
Two transformed BL-21 stains containing the
expression vectors, pET32a-S469−749 and PET32a-
S469−749, were inoculated into 500 mL of LB broth
containing kanamycin of 100 µg/mL. Being shaken,
the cultures grew to an optical density of 0.6-0.8 at
600 nm at 37C, and IPTG was added to a final con-
centration of 1 mM. The bacteria were incubated at
37˚C for additional 4-6 h and harvested, followed by
centrifugation at 4,000 g for 10 min to get the bacte-
rial pellets. The pellets were resuspended in a 10-mL
binding buffer containing 20 mM Tris-HCl, pH 7.9,
200 mM NaCl, and 5 mM imidazole. The buffer was
then lysed by sonication for 3 min. The bacterial pel-
lets containing inclusion bodies were dissolved in the
binding buffer containing 8 M urea. The recombinant
proteins were purified with an affinity chromatogra-
phy, Ni-NTA (Qiagen), with 100 mM imidazole.
The recombinant proteins were separated by SDS-
PAGE (10%) and transferred onto PVDF membranes.
The membranes were blocked by 3% BSA in Tris 100
mM, NaCl 120 mM, 0.1% Tween-20, pH 7.9 (TTBS),
and then were incubated with the sera from SARS
patients as the primary antibody. An anti-human
IgG conjugated with alkaline phosphatase was used as
the second antibody. The immunoprecipitated bands
were developed using a substrate mixture of NBT and
BCIP.
ELISA experiments were carried out according to
conventional protocol. In brief, the purified fusion
protein was mixed with sample dilution buffer, em-
bedded in 96-well ELISA plates, and incubated at
37˚C for 30 min. Then the wells were washed for
five times with washing buffer and incubated with
the sera from either SARS patients or normal con-
trols. Each well was washed and incubated with
peroxidase-conjugated goat anti-human IgG at 37˚C
for 20 min. Finally the wells were washed again with
PBS containing 0.5% Tween-20. The peroxidase re-
action was visualized using the o-pheylenediamine so-
lution as substrate. After 10 min of incubation at
37˚C, the reaction was stopped by the addition of
50 µL of 4 M sulphuric acid, and optical density at
450 nm with a reference wavelength of 630 nm was
measured by using an automatic ELISA plate reader
(Multiskan Microplate Photometer, Finland).
On SDS-PAGE, the protein bands stained by
Commassie Blue corresponding to the immunostain-
ing signals in Western blot were excised, successively
destained and dehydrated with 50% acetonitrile. The
proteins were reduced with 10 mM DTT at 56˚C for
1 h and alkylated by 55 mM iodoacetamide in dark at
room temperature for 45 min. Finally, the gel slices
were thoroughly washed with 25 mM ammonium bi-
carbonate in water/acetonitrile (50/50) solution and
were completely dried in a Speedvac. Proteins were
digested in 25 µL of modified trypsin solution (10
ng/µL in 25 mM ammonium bicarbonate) by incu-
bation overnight at 37˚C.
The digested peptides were directly loaded and an-
alyzed by LC-MS/MS using a LCQ DecaXP ion trap
mass spectrometer (ThermoFinnigan, Finland). A
linear gradient elution program was conducted to sep-
arate the peptides, delivering buffer A (0.1% formic
acid in water) from 98% to 20% and buffer B (0.1%
formic acid in acetonitrile) from 2% to 60% within
66 min. After HPLC, the eluant was split and intro-
duced to the mass spectrometer with a flow rate of
about 2 µL/min. The spray voltage was 3.2 kV and
the heated desolvation capillary was set to 150˚C.
The m/z range from 400-2,000 was scanned in 1.2
sec, and the ions were detected with a high energy
Conversion Dynode detector. The LC-MS/MS data
were converted into DTA-format files and submitted
to the searching software, TurboSEQUEST. Protein
searches were performed by comparing experimental
data with the protein database of SARS-coronavirus
generated by Beijing Genomics Institute.
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